MedPath

Gannex Pharma Co.,Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:1
Completed:8

Trial Phases

2 Phases

Phase 1:8
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
8 (72.7%)
Phase 2
3 (27.3%)

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects

Phase 1
Completed
Conditions
Chronic Weight Management
Interventions
Drug: Matching placebo
First Posted Date
2024-05-24
Last Posted Date
2025-05-11
Lead Sponsor
Gannex Pharma Co., Ltd.
Target Recruit Count
28
Registration Number
NCT06427590
Locations
🇦🇺

Ascletis, Herston, Queensland, Australia

Drug Interaction Study of ASC42 With Atorvastatin

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-07-19
Last Posted Date
2024-04-03
Lead Sponsor
Gannex Pharma Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05464628
Locations
🇺🇸

ICON, San Antonio, Texas, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Phase 2
Active, not recruiting
Conditions
Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Interventions
Drug: 2mg of ASC41
Drug: 4mg of ASC41 (2 tablets of 2 mg ASC41)
Drug: Placebo
First Posted Date
2022-07-18
Last Posted Date
2025-01-08
Lead Sponsor
Gannex Pharma Co., Ltd.
Target Recruit Count
183
Registration Number
NCT05462353
Locations
🇨🇳

The affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: ASC61 400 mg
Drug: ASC61 600 mg
Drug: ASC61 200 mg 2
Drug: ASC61 200 mg 1
Drug: ASC61 300 mg
First Posted Date
2022-03-18
Last Posted Date
2024-04-03
Lead Sponsor
Gannex Pharma Co., Ltd.
Target Recruit Count
16
Registration Number
NCT05287399
Locations
🇺🇸

California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, United States

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Phase 2
Completed
Conditions
Primary Biliary Cholangitis
Interventions
Drug: ASC42 15 mg
Drug: Placebo
Drug: ASC42 5 mg
Drug: ASC42 10 mg
First Posted Date
2022-01-13
Last Posted Date
2024-04-04
Lead Sponsor
Gannex Pharma Co., Ltd.
Target Recruit Count
98
Registration Number
NCT05190523
Locations
🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.